Search

Aim: Sarcoidosis is a systemic inflammatory disease and characterized by the presence of non-caseating granulomas which may affect all organs in the body. Some studies suggest an association between peptides and sarcoidosis. The goal of the study was to investigate the biomarker values of serum hemokinin-1 (HK-1) and adropin levels in sarcoidosis and to assess their role in the disease course. Patients and Methods: The study was carried out in a university hospital between April 2021 and February 2022. Thirty-eight patients with diagnosed sarcoidosis (14 men and 24 women) and 38 healthy (14 men and 24 women) individuals were enrolled in the study. Demographic characteristics, age, gender, disease duration, and extrapulmonary involvement of the patients were enrolled. HK-1 and adropin levels were measured via the sandwich ELISA (enzyme linked immunosorbent assay) method. Results: HK-1 level was elevated in the sarcoidosis patients than in the healthy individuals, these differences were significant statistically (0.67±0.23 and 0.54±0.24 ng/ml, p=0.012). The serum levels of adropin were measured as 207.84±246.72 ng/L in the sarcoidosis patients group and 151.16±171.76 ng/L in the healthy individuals group. No significant differences were determined in terms of the adropin levels in the patient's group when compared to the healthy individuals group (p=0.076). Serum adropin were negatively correlated with BAL CD4+ levels (r=-,880 and p=0.002) and positively correlated with BAL CD8+ levels (r=,697 and p=0.037). Conclusions: At the study, it is determined that patients with sarcoidosis show significantly higher HK-1 levels than healthy controls, and HK-1 may be a useful non-invasive diagnostic biomarker for this disease. From the literature, serum HK-1 and adropin levels have not been investigated in sarcoidosis, yet. To clarify this topic, further and larger size studies are needed.

Aim: Sarcoidosis is a systemic inflammatory disease and characterized by the presence of noncaseating granulomas which may affect all organs in the body. Some studies suggest an association between peptides and sarcoidosis. The goal of the study was to investigate the biomarker values of serum hemokinin-1 (HK-1) and adropin levels in sarcoidosis and to assess their role in the disease course. Patients and Methods: The study was carried out in in the Chest Diseases Clinic, Faculty of Medicine hospital, Necmettin Erbakan University, Konya between April 2021 and February 2022. Thirty-eight patients with diagnosed sarcoidosis (14 men and 24 women) and 38 healthy (14 men and 24 women) individuals were enrolled in the study. Demographic characteristics, age, gender, disease duration, and extrapulmonary involvement of the patients were enrolled. HK-1 and adropin levels were measured via the sandwich ELISA (enzyme linked immunosorbent assay) method. Results: HK-1 level was elevated in the sarcoidosis patients than in the healthy individuals, these differences were significant statistically (0.67±0.23 and 0.54±0.24 ng/ml, p=0.012). The serum levels of adropin were measured as 207.84±246.72 ng/L in the sarcoidosis patients group and 151.16±171.76 ng/L in the healthy individuals group. No significant differences were determined in terms of the adropin levels in the patient’s group when compared to the healthy individuals group (p=0.076). Serum adropin were negatively correlated with BAL CD4+ levels (r=-,880 and p=0.002) and positively correlated with BAL CD8+ levels (r=,697 and p=0.037). Conclusions: At the study, it is determined that patients with sarcoidosis show significantly higher HK-1 levels than healthy controls, and HK-1 may be a useful non-invasive diagnostic biomarker for this disease. From the literature, serum HK-1 and adropin levels have not been investigated in sarcoidosis, yet. To clarify this topic, further and larger size studies are needed. [ABSTRACT FROM AUTHOR]

Copyright of Der Internist is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Aim: To introduce the range of eye changes in sarcoidosis in the individual casuistics., Materials: At the Ophthalmic Clinic of Teaching Hospital Královské Vinohrady in Prague were examined and treated six patients with ocular forms of sarcoidosis in the years from 1998 to 2015. Three patients were unilateral lesions of the lacrimal gland without systemic symptoms. One patient experienced orbital inflammatory syndrome that accompanied the hilar form of pulmonar sarcoidosis. Two other patients underwent intraocular inflammation, panuveitis / iridocyclitis and bilateral intermedial uveitis. Both of these patients also had systemic affections of mediastinal lymph nodes and lung, in the first of these, signs of neurosarcoidosis first appeared., Results: In the treatment of lacrimal glands, the diagnosis was determined by histological examination of the removed lacrimal gland in external orbitotomies, also, the orbital process has been verified by biopsy and the subsequent comprehensive examination revealed the systemic process. Definitive diagnosis of sarcoidosis was established bioptically in both uveitides and has also been demonstrated in imaging methodologies including galli scintigraphy. All patients were successfully treated with corticosteroid therapy., Conclusion: Biopsy results have always been a surprise in orbital processes. Both cases of uveitis were associated with systemic involvement and initiated comprehensive investigation which showed the need for interdisciplinary collaboration in the diagnosis and treatment of sarcoidosis. Key words: sarkoidosis, biopsy, corticosteroids, gallii scintigraphy, MRI, uveitis.